Top 5 Articles of the Month: February

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

1. Expanding NP and PA Opportunities in Dermatology Practice

At the inaugural Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, discussed how NPs and PAs can advance their professional growth by seizing opportunities to share their clinical experiences.

“Include us in ad boards. Include us in publishing. Include us in poster creation. We want to be able to do all the things that our MD counterparts are doing. We’re not trying to be them, but we want to rub shoulders with them. We want to have the same chances to grow professionally that they have,” DiRuggiero said in an interview with Dermatology Times at the Horizons in Advanced Practice meeting in Las Vegas, Nevada.

2. Dermatology Conferences and Meetings Calendar: 2025

Dermatology Times has asked our readers to share with us what conferences and meetings they are looking forward to or planning to attend in 2025. Using these responses, we have compiled a list of dermatological meetings taking place this year.

3. Q&A: Pelage's Novel PP405 Advances to Phase 2a for Androgenetic Alopecia

Pelage Pharmaceuticals recently announced its novel topical agent, PP405, has advanced to a phase 2a study for androgenetic alopecia, with enrollment currently underway at sites across the US. It also shared that the company has secured an additional $14 million in Series A-1 funding, led by GV and supported by Main Street Advisors, Visionary Ventures, and YK BioVentures.

Dermatology Times recently spoke with Qing Yu Christina Weng, MD, chief medical officer of Pelage, who discussed the proof of mechanism of PP405, support for advancement into phase 2, and the importance of having a diverse patient pool.

4. The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia

Last month, Eirion Therapeutics announced positive results for its first-in-man clinical trial of topical ET-02 in the treatment of androgenic alopecia. The drug was safe and well-tolerated, with unprecedented results being observed as early as 5 weeks.

Dermatology Times recently spoke with Jon Edelson, MD, CEO and President of Eirion. He shared groundbreaking insights into the therapeutic potential of ET-02, its mechanism of action, and how it aims to revolutionize the treatment landscape for hair loss.

5. Paul Friedman, MD: An In-Depth Review of UltraClear Laser-Coring

UltraClear Laser-Coring is a “first-of-its-kind" advanced technique that targets deep wrinkles and scars to help smooth patients’ skin. With less bleeding and downtime, UltraClear Laser-Coring is convenient for both the dermatology clinician and the patient.

Paul Friedman, MD, a board-certified dermatologist, Mohs surgeon, and director of the Dermatology & Laser Surgery Center in Houston, Texas, recently spoke to Dermatology Times to review in-depth UltraClear Laser-Coring, its main benefits, patient downtime, advice for clinicians starting their aesthetic device journey, and how to decide what devices to have in each clinic.